Trial Search Results

Brain Oxygen Optimization in Severe TBI, Phase 3

BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in standard care. It is unknown if one is more effective than the other. In both strategies the monitoring and goals help doctors adjust treatments including the kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. The results of this study will help doctors discover if one of these methods is more safe and effective.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan

Collaborator: Medical University of South Carolina

Stanford Investigator(s):

Intervention(s):

  • Other: ICP + PbtO2 guided management strategy
  • Other: ICP guided management strategy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Non-penetrating traumatic brain injury

   - Glasgow Coma Scale (GCS) 3-8 measured off paralytics

   - Glasgow Coma Scale motor score < 6 if endotracheally intubated

   - Evidence of intracranial trauma on CT scan

   - Able to place intracranial probes and randomize within 6 hours of arrival at enrolling
   hospital

   - Able to place intracranial probes and randomize within 12 hours from injury

   - Age greater than or equal to 14 years

Exclusion Criteria:

   - Non-survivable injury

   - Bilaterally absent pupillary response in the absence of paralytic medication

   - Contraindication to the placement of intracranial probes

   - Treatment of brain tissue oxygen values prior to randomization

   - Planned use of devices which may unblind treating physicians to brain tissue hypoxia

   - Systemic sepsis at screening

   - Refractory hypotension

   - Refractory systemic hypoxia

   - PaO2/FiO2 ratio < 200

   - Known pre-existing neurologic disease with confounding residual neurological deficits

   - Known inability to perform activities of daily living (ADL) without assistance prior
   to injury

   - Known active drug or alcohol dependence that, in the opinion of site investigator,
   would interfere with physiological response to brain tissue oxygen treatments

   - Pregnancy

   - Prisoner

   - On EFIC Opt-Out list as indicated by a bracelet or medical alert

Ages Eligible for Study

14 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
James Quinn
650-736-4391
Recruiting